Amphastar Pharmaceuticals, INC Form 4 insider transactions

William J. Peters, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, exercised stock options and sold shares on November 6, 2024, according to a Form 4 filing with the SEC.

Senior EVP Rong Zhou of Amphastar Pharmaceuticals reports exercising stock options and selling shares on September 13, 2024.

Jack Y. Zhang, CEO of Amphastar Pharmaceuticals, exercised stock options and reported changes in beneficial ownership of company stock.

Director Floyd F. Petersen of Amphastar Pharmaceuticals sold 3,000 shares of common stock at a weighted average price of $46.4724 on September 5, 2024.

Senior EVP Rong Zhou of Amphastar Pharmaceuticals reports the acquisition and disposal of company stock, including transactions related to employee stock options and the employee stock purchase plan.

Richard K. Prins, a director at Amphastar Pharmaceuticals, executed stock option exercises and sales on August 12, 2024, resulting in changes to his beneficial ownership.

William J. Peters, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, exercised stock options and sold shares on July 31, 2024, according to a Form 4 filing with the SEC.

William J. Peters, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, sold shares of common stock on June 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.

CEO Jack Y. Zhang exercised employee stock options and reported changes in beneficial ownership of Amphastar Pharmaceuticals stock, as detailed in a Form 4 filing with the SEC.

Floyd F. Petersen, a director at Amphastar Pharmaceuticals, sold 3,000 shares of common stock at $41.40 per share on June 10, 2024.

Director Lee Howard reports acquisition and disposal of Amphastar Pharmaceuticals stock and stock options.

Diane G. Gerst, a director at Amphastar Pharmaceuticals, reports acquiring common stock and stock options on June 3, 2024.

Director Gayle Deflin of Amphastar Pharmaceuticals reports acquisition of common stock and stock options.

Director Floyd F. Petersen of Amphastar Pharmaceuticals reports the sale of 500 shares and acquisition of 3,076 restricted stock units, along with an option to purchase 6,864 shares.

Yakob Liawatidewi, EVP Corp Admin Center at Amphastar Pharmaceuticals, reports the withholding of shares for tax liability and shares acquired through the employee stock purchase plan.

Director Richard K. Prins acquired 3,076 shares of common stock and 6,864 stock options in Amphastar Pharmaceuticals on June 3, 2024.

Director Michael Zasloff reported the acquisition of restricted stock units and stock options in Amphastar Pharmaceuticals.

William J. Peters, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, Inc., reports a transaction involving the withholding of shares to cover tax liabilities related to vested restricted stock units.

Director Floyd F. Petersen sold 500 shares of Amphastar Pharmaceuticals (AMPH) at an average price of $41.6739 on May 1, 2024, under a pre-arranged 10b5-1 trading plan.

Director Floyd F. Petersen sold 500 shares of Amphastar Pharmaceuticals (AMPH) at a weighted average price of $43.4283 on April 1, 2024, under a pre-arranged 10b5-1 trading plan.

Jack Y. Zhang and Mary Z. Luo, key executives at Amphastar Pharmaceuticals, exercised stock options and sold shares to cover associated tax liabilities.

Yakob Liawatidewi, EVP Corp Admin Center at Amphastar Pharmaceuticals, reported disposing of shares to cover tax liabilities related to vesting restricted stock units.

Senior EVP Zhou Rong of Amphastar Pharmaceuticals reports disposing of shares to cover tax liabilities related to vesting restricted stock units.

William J. Peters, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, reported the disposal of common stock to cover tax liabilities related to the vesting of restricted stock units.

William Peters, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, exercised stock options and sold shares on March 6, 2024, according to a Form 4 filing with the SEC.

Yakob Liawatidewi, EVP Corp Admin Center at Amphastar Pharmaceuticals, reports the withholding of 1,221 shares to cover tax liabilities related to vesting restricted stock units.

Senior EVP Rong Zhou of Amphastar Pharmaceuticals reports disposition of shares to cover tax obligations related to vesting of restricted stock units.

Jack Y. Zhang, CEO, and Mary Z. Luo, COO, of Amphastar Pharmaceuticals, reported disposing of shares to cover tax liabilities related to vesting restricted stock units.

Amphastar Pharmaceuticals' CEO Jack Y. Zhang and COO Mary Z. Luo receive stock options and restricted stock units (RSUs) vesting annually starting March 4, 2025.

Director Michael Zasloff of Amphastar Pharmaceuticals sold a total of 12,500 shares of common stock on March 5, 2024, in two separate transactions.